FDA
-
-
-
-
-
-
-
Clovis Oncology (CLVS) Reports Updated LuMIERE Phase 1 FAP-2286 Data
-
-
-
-
-
-
-
Clovis Oncology Submits Applications for Rubraca® Label Expansion in the US and European Union as First-line Maintenance Treatment in Women with Advanced Ovarian Cancer
-
-
-
-
-
-
-
Clovis Oncology's (CLVS) Rubraca as First-Line Maintenance Treatment Significantly Improves PFS in Women with Advanced Ovarian Cancer in Primary Efficacy Analyses Regardless of BRCA Mutation and HRD S
-
-
-
-
-
-
-
Clovis Oncology (CLVS) Reports Rubraca Significantly Improves Progression-Free Survival in First-line Maintenance Treatment in Women with Ovarian Cancer Regardless of Their Biomarker Status in Phase 3
-
-
-
-
-
-
-
Clovis Oncology Announces Preliminary Financial Results for the Fourth Quarter and Full Year 2021
-
-
-
-
-
-
-
Clovis Oncology (CLVS) Announces Pan-Cancer Analysis Suggests Fibroblast Activation Protein is Attractive Target for Peptide-Targeted Radionuclide Therapy with FAP-2286
-
-
-
-
-
-
-
Clovis Oncology (CLVS) Initial Clinical Experience of FAP-2286 in Independent Named Patient Use Published in The Journal of Nuclear Medicine
-
312,667 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

